{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:09:31Z","timestamp":1772003371107,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with chronic kidney disease have a high risk of fracture, but evidence-based treatment protocols for osteoporosis are lacking. Bisphosphonates are commonly used anti-resorptive drugs, but due to renal excretion, patients with chronic kidney disease have not been included in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present a case of severe bone fragility in a patient on long-term hemodialysis therapy where zoledronate was well-tolerated and provided clinical improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the potential role of bisphosphonates in chronic kidney disease\u2013associated osteoporosis and the need for trials to establish the safety and efficacy of anti-resorptive drugs in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01680-2","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:26:23Z","timestamp":1772000783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zoledronic acid for chronic kidney disease\u2013associated osteoporosis"],"prefix":"10.1007","volume":"21","author":[{"given":"Sukanya","family":"Sakthivel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista Dybtved","family":"Kj\u00e6rgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Ivarsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne Skou","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/ndt\/gfw073","volume":"31","author":"D Hansen","year":"2016","unstructured":"Hansen D, Olesen JB, Gislason GH, Abrahamsen B, Hommel K (2016) Risk of fracture in adults on renal replacement therapy: a Danish national cohort study. Nephrol Dial Transplant 31:1654\u20131662. https:\/\/doi.org\/10.1093\/ndt\/gfw073","journal-title":"Nephrol Dial Transplant"},{"key":"1680_CR2","doi-asserted-by":"publisher","unstructured":"Jorgensen HS, David K, Salam S, Evenepoel P, European Renal Osteodystrophy workgroup, an initiative of the CKD-MBD working group of the ERA-EDTA (2021) Traditional and non-traditional risk factors for osteoporosis in CKD. Calcif Tissue Int 108:496\u2013511. https:\/\/doi.org\/10.1007\/s00223-020-00786-0","DOI":"10.1007\/s00223-020-00786-0"},{"key":"1680_CR3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.xkme.2021.07.005","volume":"3","author":"IA Portales-Castillo","year":"2021","unstructured":"Portales-Castillo IA et al (2021) Prescription patterns of osteoporosis medications in patients with advanced CKD: a retrospective cohort study. Kidney Med 3:1112\u20131115. https:\/\/doi.org\/10.1016\/j.xkme.2021.07.005","journal-title":"Kidney Med"},{"key":"1680_CR4","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/bph.15024","volume":"178","author":"BL Langdahl","year":"2021","unstructured":"Langdahl BL (2021) Overview of treatment approaches to osteoporosis. Br J Pharmacol 178:1891\u20131906. https:\/\/doi.org\/10.1111\/bph.15024","journal-title":"Br J Pharmacol"},{"key":"1680_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","volume":"331","author":"ST Bird","year":"2024","unstructured":"Bird ST et al (2024) Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA 331:491\u2013499. https:\/\/doi.org\/10.1001\/jama.2023.28239","journal-title":"JAMA"},{"key":"1680_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16775","volume":"7","author":"SBK Jensen","year":"2024","unstructured":"Jensen SBK et al (2024) Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open 7:e2416775. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.16775","journal-title":"JAMA Netw Open"},{"key":"1680_CR7","doi-asserted-by":"publisher","unstructured":"Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline update: what\u2019s changed and why it matters. Kidney Int 92:26\u201336. Kidney Int 92:1558.\u00a0https:\/\/doi.org\/10.1016\/j.kint.2017.10.001","DOI":"10.1016\/j.kint.2017.10.001"},{"key":"1680_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","volume":"107","author":"M Ketteler","year":"2025","unstructured":"Ketteler M et al (2025) Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 107:405\u2013423. https:\/\/doi.org\/10.1016\/j.kint.2024.11.013","journal-title":"Kidney Int"},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7326\/M24-0013","volume":"178","author":"ST Bird","year":"2025","unstructured":"Bird ST et al (2025) The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease\u202f: A target trial emulation. Ann Intern Med 178:29\u201338. https:\/\/doi.org\/10.7326\/M24-0013","journal-title":"Ann Intern Med"},{"key":"1680_CR10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"key":"1680_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020831","volume":"99","author":"X Dai","year":"2020","unstructured":"Dai X, Deng Y, Luo Y, Xie J, Ma H (2020) Effect of different hydration doses on renal function in patients with primary osteoporosis treated with zoledronic acid: a hospital-based retrospective cohort study. Medicine (Baltimore) 99:e20831. https:\/\/doi.org\/10.1097\/MD.0000000000020831","journal-title":"Medicine (Baltimore)"},{"key":"1680_CR12","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150\u20133157. https:\/\/doi.org\/10.1200\/JCO.2003.04.105","journal-title":"J Clin Oncol"},{"key":"1680_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00198-021-06160-6","volume":"33","author":"M Schini","year":"2022","unstructured":"Schini M et al (2022) Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporos Int 33:737\u2013744. https:\/\/doi.org\/10.1007\/s00198-021-06160-6","journal-title":"Osteoporos Int"},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/hdi.12773","volume":"23","author":"K Iseri","year":"2019","unstructured":"Iseri K et al (2019) Elimination of intravenous alendronate by hemodialysis: a kinetic study. Hemodial Int 23:466\u2013471. https:\/\/doi.org\/10.1111\/hdi.12773","journal-title":"Hemodial Int"},{"key":"1680_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jbmr\/zjae193","volume":"40","author":"K Iseri","year":"2025","unstructured":"Iseri K, Hida N (2025) Risk factors for osteonecrosis of the jaw in patients with chronic kidney disease: a nested case-control study. J Bone Miner Res 40:262\u2013269. https:\/\/doi.org\/10.1093\/jbmr\/zjae193","journal-title":"J Bone Miner Res"},{"key":"1680_CR16","doi-asserted-by":"publisher","unstructured":"Ok E et al (2015) Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.2015030268","DOI":"10.1681\/ASN.2015030268"},{"key":"1680_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.7326\/ANNALS-24-03237","volume":"178","author":"S Masuda","year":"2025","unstructured":"Masuda S, Fukasawa T, Matsuda S, Kawakami K (2025) Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis\u202f: a target trial emulation. Ann Intern Med 178:167\u2013176. https:\/\/doi.org\/10.7326\/ANNALS-24-03237","journal-title":"Ann Intern Med"},{"key":"1680_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bonr.2018.03.005","volume":"8","author":"A Bhan","year":"2018","unstructured":"Bhan A, Qiu S, Rao SD (2018) Bone histomorphometry in the evaluation of osteomalacia. Bone Rep 8:125\u2013134. https:\/\/doi.org\/10.1016\/j.bonr.2018.03.005","journal-title":"Bone Rep"},{"key":"1680_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jbmr.309","volume":"26","author":"HH Malluche","year":"2011","unstructured":"Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26:1368\u20131376. https:\/\/doi.org\/10.1002\/jbmr.309","journal-title":"J Bone Miner Res"},{"key":"1680_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1681\/ASN.2021081081","volume":"33","author":"H J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen H et al (2022) Natural history of bone disease following kidney transplantation. J Am Soc Nephrol 33:638\u2013652. https:\/\/doi.org\/10.1681\/ASN.2021081081","journal-title":"J Am Soc Nephrol"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01680-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01680-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01680-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:26:24Z","timestamp":1772000784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01680-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01680-2","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written patient consent was obtained prior to publication of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bente Langdahl has received honoraria for advisory boards and lectures from UCB, Gedeon Richter, Mereo, Samsung Bioepis, and Angitia. Per Ivarsen has received honoraria for advisory boards and lectures from CSL Vifor, Alexion, Swedish Orphan, and Otsuka. Hanne Skou J\u00f8rgensen has received travel support from Abiogen Pharma and lecture fees from UCB. Krista Dybtved Kj\u00e6rgaard and Sukanya Sakthivel declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"45"}}